Guidelines update, version 34.1

• Dutasteride – preprint publication status has been removed from the summary information to reflect publication of the included trial by Cadegiani et al. The time to recovery data and number of included patients has been updated with no change to strength or direction of recommendation.

• Azithromycin – additional study added to the summary information:

We have found one new study comparing azithromycin with standard care (Rashad et al. Res Sq doi: 10.21203/rs.3.rs-181996/v1). 

• Hydroxychloroquine – three additional studies have been added to the summary information:

We have found three new studies comparing hydroxychloroquine with placebo or standard care (Omrani et al. EClinMed doi: 10.1016/j.eclinm.2020.100645, Ader et al. medRxiv doi: 10.1101/2021.01.08.20248149 and Hernandez-Cardenas et al. medRxiv doi: 10.1101/2021.02.01.21250371). 

• Intravenous immunoglobulin – additional study added to the summary information:

We have found one new study comparing intravenous immunoglobulin with standard care (Raman et al. J Infect Dis doi: 10.1093/infdis/jiab098).

• Ivermectin – additional study (Shah Bukhari et al.) added to the summary information:

We have found two new studies comparing ivermectin with standard care (Mohan et al. Res Sq doi: 10.21203/rs.3.rs-191648/v1 and Shah Bukhari et al. medRxiv doi: 10.1101/2021.02.02.21250840). 

Note: The newly identified studies listed above are currently under review and updated recommendations will be included in future versions of the guidelines.